Obstructive vs Restrictive Lung Disease — USMLE High-Yield Review
Obstructive and restrictive lung diseases are separated by their pulmonary function testing (PFT) signature: obstructive disease produces airflow limitation (low FEV1/FVC), while restrictive disease produces reduced lung volumes (low TLC and FVC with a preserved or elevated FEV1/FVC). The framework is to confirm the pattern objectively, then localize the disease—airways versus parenchyma versus extrapulmonary—using DLCO and HRCT, because management diverges sharply between categories.
The Spirometry Framework
Obstructive disease is defined spirometrically by FEV1/FVC below 0.70 (or below the lower limit of normal, which adjusts for age). In COPD, some bronchodilator response can be present but does not exclude the diagnosis. Restrictive disease shows the opposite: reduced TLC and FVC with a normal or elevated FEV1/FVC ratio. Critically, spirometry alone can be misleading for restriction—confirm restriction with lung volumes (TLC). Never assume 'wheezing = asthma'; always confirm the diagnosis with objective testing.
Obstructive Lung Diseases
The obstructive diseases share airflow limitation but differ in pathophysiology. COPD combines emphysema (parenchymal destruction) with chronic bronchitis (airway disease), is usually from smoking (occasionally alpha-1 antitrypsin deficiency), and is largely irreversible. Suspect AAT deficiency in a young (<45), minimal/non-smoker with lower-lobe panacinar emphysema, versus typical upper-lobe smoking-related emphysema. Asthma is fundamentally different: reversible (at least partial) airway obstruction with bronchial hyperresponsiveness driven by Th2 inflammation (IL-4, IL-5, IL-13; IgE; eosinophils). Its obstruction has three components—smooth muscle contraction (rapidly reversible), airway wall edema, and mucus plugging—with chronic disease causing remodeling (smooth muscle hypertrophy, subepithelial fibrosis, goblet cell hyperplasia) and partially irreversible obstruction. Bronchiectasis is permanent airway dilation (the 'signet ring sign' on CT) from chronic infection/inflammation, presenting with copious productive cough; it is a consequence, not a diagnosis, so always search for an underlying cause (cystic fibrosis, immunodeficiency, ABPA, PCD).
Restrictive Lung Diseases
Restrictive lung diseases show reduced lung volumes due to either intrinsic parenchymal disease (interstitial lung disease) or extrinsic factors limiting lung expansion. The diagnostic approach starts with a detailed history (occupational/environmental exposures, medications, connective tissue disease symptoms, smoking, family history), then physical exam clues such as fine 'Velcro-like' basilar crackles and clubbing in pulmonary fibrosis. PFTs show the restrictive pattern (reduced TLC and FVC, normal or elevated FEV1/FVC) with a reduced DLCO—the most sensitive marker, reflecting loss of alveolar-capillary surface area. HRCT is the cornerstone of ILD diagnosis; specific patterns (e.g., UIP in IPF) can be diagnostic and guide biopsy. Laboratory testing (ANA, RF, anti-CCP, anti-Scl-70, anti-Jo-1, serum precipitins, ACE) and, when needed, BAL or surgical lung biopsy complete the workup.
DLCO: Localizing the Lesion
DLCO differentiates intrinsic from extrinsic restriction. In intrinsic parenchymal disease (ILD), DLCO is reduced because the alveolar-capillary interface is destroyed. A normal DLCO in a patient with restriction suggests the lungs themselves are normal and the problem is extrapulmonary (chest wall, neuromuscular, or pleural limitation of expansion). DLCO also carries prognostic and diagnostic weight in obstructive disease—it is reduced in emphysema from loss of surface area.
Management Diverges by Category
Obstructive management is bronchodilator-centered. In COPD, all patients get a SABA for rescue; maintenance escalates from LAMA or LABA monotherapy to dual LAMA+LABA, adding an inhaled corticosteroid for frequent exacerbators or blood eosinophils ≥300 (ICS increases pneumonia risk in COPD). Smoking cessation is the only intervention proven to slow COPD progression. In asthma, ICS is the cornerstone of therapy. Restrictive/ILD treatment is diagnosis-specific and can be the opposite of intuition: IPF is treated with antifibrotics (pirfenidone, nintedanib), and traditional immunosuppression is harmful (increased mortality in PANTHER-IPF) because IPF is aberrant fibrosis, not inflammation. In contrast, CTD-ILD is treated with immunosuppression, hypersensitivity pneumonitis with antigen avoidance ± steroids, and pneumoconiosis with exposure removal and supportive care. Lung transplant is the only curative option for IPF, now the most common indication for lung transplant.
High-yield
- Obstructive = low FEV1/FVC (<0.70); restrictive = low TLC/FVC with normal or elevated FEV1/FVC.
- Confirm restriction with lung volumes (TLC)—spirometry alone can mislead.
- DLCO is the most sensitive marker in ILD and differentiates intrinsic (low DLCO) from extrinsic (normal DLCO) restriction.
- HRCT is the cornerstone of ILD diagnosis; UIP pattern suggests IPF.
- AAT deficiency: young non-smoker with lower-lobe panacinar emphysema (vs upper-lobe smoking emphysema).
- Asthma is reversible, Th2/IgE/eosinophil-driven; COPD is largely irreversible and smoking-related.
- 'Velcro-like' basilar crackles and clubbing point to pulmonary fibrosis.
- Bronchiectasis: 'signet ring sign,' copious sputum—always hunt the underlying cause.
- IPF: antifibrotics (pirfenidone, nintedanib) work; immunosuppression harms (PANTHER-IPF).
- COPD maintenance: bronchodilators first; add ICS for exacerbators with eosinophils ≥300 (ICS raises pneumonia risk).
Pitfalls
- Assuming 'wheezing = asthma'—always confirm with objective testing and consider COPD or overlap.
- Relying on spirometry alone to diagnose restriction instead of confirming with TLC.
- Treating IPF with corticosteroids/immunosuppression—this increased mortality and worsens outcomes.
- Forgetting that bronchiectasis is a consequence, not a diagnosis, and skipping the search for an underlying cause.
- Interpreting a normal DLCO in a restrictive patient as parenchymal disease—it actually points to an extrapulmonary cause.
- Overusing ICS in COPD, forgetting it increases pneumonia risk; reserve for eosinophilia/frequent exacerbations.
- Missing AAT deficiency by not testing young non-smokers with lower-lobe emphysema.
Turn this into reasoning you can use on exam day — practice Obstructive vs Restrictive Lung Disease on branching cases where your decisions shape the patient.